{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-169021","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.339385+00:00","generated_at":"2026-06-13T22:37:43.165070+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Tempest Therapeutics stockholders approve equity plan expansion and re-elect directors at 2023 annual meeting","bullets":["Stockholders approved Amended and Restated 2023 Equity Incentive Plan, increasing authorized shares by 1,150,000.","Re-elected Thomas Dubensky and Christine Pellizzari as Class II directors to serve until 2026.","Advisory vote on executive compensation approved with 7,355,907 votes for, 55,375 against.","Ratified Ernst & Young as independent registered public accounting firm for fiscal 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-169021","json":"https://secwatch.observer/filing/0001193125-23-169021.json","markdown":"https://secwatch.observer/filing/0001193125-23-169021.md","text":"https://secwatch.observer/filing/0001193125-23-169021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/d512429d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:37:43.165070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"231827abf453ec2ba59e0677bbe41e8e0a3f058c","claim":"Tempest Therapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s stockholders elected the persons listed below as a Class II directors, to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"},{"claim_id":"30d2de9fe014e48a35cf9d58c540a7871d66c144","claim":"Tempest Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"},{"claim_id":"36f559f8e4310c125f26c68c60ba757b95bc0d49","claim":"Tempest Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"},{"claim_id":"4fa412369c7b2ba03701d3b5dd81615396cb0a2e","claim":"Tempest Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2023 Equity Incentive Plan at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s stockholders ratified the 2023 EIP, which amends, restates and will be a successor to, and replacement of, the 2019 EIP.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}